Not wellness.
Science.
Every protocol WellSpry offers is grounded in peer-reviewed clinical evidence. Here's what we've built on.
GLP-1 Metabolic Monitoring
SCALE trial (2021): Semaglutide patients with structured metabolic monitoring maintained 87% of weight loss at 12 months vs 61% without monitoring
Peptide Efficacy
Ipamorelin/CJC-1295 combination: mean 18% increase in IGF-1 at 12 weeks in adults 35–65 (Sigalos & Pastuszak, 2018)
Biological Age Testing
GrimAge clock: strongest predictor of all-cause mortality among epigenetic clocks (Lu et al, 2019, Nature Aging)
Key studies
How we translate evidence into protocols
Every WellSpry protocol begins with a systematic literature search across PubMed, NEJM, and Cochrane. Our clinical advisory panel evaluates study quality, sample size, follow-up duration, and effect size before any marker or compound reaches a patient panel.
Physician oversight is non-negotiable. No protocol is adopted based on in vitro data alone, anecdotal reports, or industry-funded research without independent replication. Each intervention requires at least one well-powered RCT or prospective cohort study with clearly defined endpoints.
Protocols are versioned and updated quarterly. When new data emerges that contradicts existing guidance, we revise recommendations and notify members directly. The evidence base is a living document — not a static founding story.
See what your biomarkers reveal
Data without interpretation is noise. WellSpry turns 72 biomarkers into a clinical picture your physician can act on.
Explore Testing Panels